90.45
+0.24
+(0.27%)
At close: April 17 at 4:46:33 PM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in EUR | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 15 | 14 |
| Avg. Estimate | 9.8B | 10.08B | 45.21B | 48.57B |
| Low Estimate | 9.6B | 9.84B | 42.93B | 46.62B |
| High Estimate | 10.47B | 10.62B | 48.23B | 51.39B |
| Year Ago Sales | 10.46B | 10.74B | 41.08B | 45.21B |
| Sales Growth (year/est) | -6.34% | -6.22% | 10.05% | 7.44% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 1SAN.MI | -- | -- | -- | -- |
| S&P 500 | 7.04% | 5.20% | 8.89% | 14.14% |
Related Tickers
LLY.DU Eli Lilly and Co
749.10
+15.41%
JNJ.DE Johnson & Johnson
138.76
+1.80%
NOVN.SW Novartis AG
90.63
+0.19%
NOV.DE Novo Nordisk A/S
51.88
-8.68%
GSK GSK plc
35.93
+1.58%
NOVO-B.CO Novo Nordisk A/S
421.25
-1.03%
NVO Novo Nordisk A/S
58.08
-7.63%
JNJ Johnson & Johnson
157.47
+2.31%
PFE Pfizer Inc.
22.14
+0.45%
ABBV AbbVie Inc.
172.99
+0.76%